WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Rishi Sunak faces backlash on prisons as government triggers emergency overcrowding planCaitlin Clark's WNBA debut helps ESPN set viewership record for league game on networkNew Kansas abortion clinic will open to help meet demand from restrictive neighboring statesNorth Carolina lawmakers push bill to ban most public mask wearing, citing crimeSebastián Driussi scores a teamSouth Africa braces for what may be a milestone election. Here is a guide to the main playersAustralian gov't confirms 2nd consecutive budget surplusCaitlin Clark's WNBA debut helps ESPN set viewership record for league game on networkInterior Dept staffer becomes first Jewish Biden appointee to publicly resign over war in GazaChildcare vs pay: The salary you need to make being a working parent profitable
2.6029s , 6499.0234375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Stellar Standpoint news portal